Updated time: 2021-02-01 18:47:36
We have recently identified from the snake venom of Daboia russelii an extremely potent heparin/heparan sulfate-dependent APC inhibitor, named DrKIn-I, that exhibits high specificity for APC inhibition. It is a member of the snake Kunitz/BPTI family and consists of 66 amino acids with three conserved disulfide linkages to stabilize the overall structure. DrKIn-I is unique among all the other Kunitz-type protease inhibitors in that it is extremely basic (predicted pI = 9.6), with two putative heparin-binding motifs in its C-terminal region (49TRKKCRQ55 and 60PRKGRP65). The presence of these -XBBBXBX- and -XBBXBX- regions (where X represents uncharged amino acids and B represents basic amino acids) probably contributes to the high affinity of DrKIn-I towards heparin/heparan sulfate chains and allows these oligosaccharides to potentiate the inhibition of APC by DrKIn-I. This novel inhibitor shows fast binding kinetics with APC, with an association rate constant of 1.3 ± 0.8 × 107 M-1s-1, and in the presence of heparin/heparan sulfate chains, it exhibits an inhibition constant (Ki) of ~50 pM. This Ki is at least 10,000-fold lower than that of the other synthetic APC inhibitors, and is the most potent APC inhibitor found to date. The inhibitory activity and specificity of this novel inhibitor has been demonstrated both in purified systems and in plasma. Furthermore, animal studies have shown that this novel inhibitor does exhibit potent procoagulant activities in vivo.
This novel Kunitz-type APC inhibitor containing a heparin-binding motif, together with the necessary modifications, should be able to provide an alternative treatment for hemophilic patients. It does not possess the risk of viral transmissions, and since this novel inhibitor is short and is unglycosylated, the manufacturing cost of this peptide should be much less.
11A-1010326
US 9,206,246
Treatment of Hemophilic patients
Inn-Hi Tsai, An-Chun Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A potent heparin/heparan sulfate-dependent inhibitor of activated protein C that can be used for the treatment of hemophilic pat